Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration Read more about Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration
Agios Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12 Read more about Agios Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12
Agios Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Over-Allotment Option Read more about Agios Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
Agios Pharmaceuticals Announces Pricing of $220 Million Public Offering of Common Stock Read more about Agios Pharmaceuticals Announces Pricing of $220 Million Public Offering of Common Stock
Agios Pharmaceuticals Announces Proposed Offering of Common Stock Read more about Agios Pharmaceuticals Announces Proposed Offering of Common Stock
Agios Pharmaceuticals Appoints Kaye Foster-Cheek to its Board of Directors Read more about Agios Pharmaceuticals Appoints Kaye Foster-Cheek to its Board of Directors
Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency Read more about Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency
Agios Announces Celgene Decision to Extend Discovery Phase of Global Strategic Collaboration to April 2016 Read more about Agios Announces Celgene Decision to Extend Discovery Phase of Global Strategic Collaboration to April 2016
Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies Read more about Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies
Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML) Read more about Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML)